1
项与 [111In]In-DOTA-ANTI-CEA antibody(Radboud University Medical Center) 相关的临床试验A Phase I/II Study to Evaluate the Safety and Feasibility of Multimodal Imaging Using a Dual-labeled Anti-CEA Antibody in Patients With Rectal or Pancreatic Cancer
Most digestive cancers show (over)expression of the tumour marker carcinoembryonic antigen (CEA). Therefore, interest in CEA-targeting tracers has increased over the past years. CEA-targeting tracers can be used for preoperative, intra-operative and postoperative imaging purposes. This study focusses on both preoperative and intraoperative multimodal imaging and image-guided surgery in patients with rectal cancer or pancreatic cancer.
100 项与 [111In]In-DOTA-ANTI-CEA antibody(Radboud University Medical Center) 相关的临床结果
100 项与 [111In]In-DOTA-ANTI-CEA antibody(Radboud University Medical Center) 相关的转化医学
100 项与 [111In]In-DOTA-ANTI-CEA antibody(Radboud University Medical Center) 相关的专利(医药)
100 项与 [111In]In-DOTA-ANTI-CEA antibody(Radboud University Medical Center) 相关的药物交易